CompletedPHASE2, PHASE3NCT03826628
Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex
Studying Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dermatology Specialties Limited Partnership
- Principal Investigator
- Ioana Stanescu, MDDermatology Specialties Limited Partnership
- Intervention
- rapamycin(drug)
- Enrollment
- 107 enrolled
- Eligibility
- 6-65 years · All sexes
- Timeline
- 2019 – 2022
Study locations (17)
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- University of California San Diego, La Jolla, California, United States
- All Children's Research Institute, St. Petersburg, Florida, United States
- Spectrum Health, Grand Rapids, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- University of Virginia, Charlottesville, Virginia, United States
- Children's Health Queensland, Brisbane, Queensland, Australia
- Fakultni nemocnice Brno, Brno, Czechia
- Bethesda Children's Hospital of the Hungarian Reformed Church, Budapest, Hungary
- University of Pécs, Pécs, Hungary
- Canterbury District Health Board, Christchurch, Canterbury, New Zealand
- Clinic of Neurology and Psychiatry for Children and Youth, Belgrade, Serbia
- Clinical Center of Serbia, Belgrade, Serbia
- Narodný ústav detských chorȏb, Bratislava, Slovakia
- Clinica Universidad de Navarra, Pamplona, Navarre, Spain
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03826628 on ClinicalTrials.govOther trials for Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07561957A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) GuidelinesSt. James's Hospital, Ireland
- RECRUITINGPHASE1NCT07369505Sapu003 in Advanced mTOR-sensitive Solid TumorsSAPU NANO (US) LLC
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06392009Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type IIGRIN Therapeutics, Inc.
- ACTIVE NOT RECRUITINGNCT02461459Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)Boston Children's Hospital
See all trials for Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis →